Immunovant, Inc.
IMVT evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $7.72B
- Cash Runway:
- 19.2 mo
What it means
What to watch
Prepared research question
What matters most for IMVT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMVT
Immunovant is a clinical-stage immunology company developing IMVT-1402, an anti-FcRn monoclonal antibody, for autoimmune diseases, with a focus on generalized myasthenia gravis and other IgG-driven conditions.
Key risk: Net loss trajectory
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Immunovant is a clinical-stage immunology company developing IMVT-1402, an anti-FcRn monoclonal antibody, for autoimmune diseases, with a focus on generalized myasthenia gravis and other IgG-driven conditions.
- Cash & equivalents of $797.8M as of 2026-06-30 [sec]
- Net income of -$153.2M for the period ending 2026-06-30 [sec]
- Shareholders' equity of $735.4M as of 2026-06-30 [sec]
- Lead asset IMVT-1402 is a fully human monoclonal antibody targeting FcRn to reduce pathogenic IgG antibodies [sec · filed 2026-07-22]
- Indefinitely delayed further development of batoclimab to focus resources on IMVT-1402 [sec_mda · as of 2026-08-06]
What works
- Cash position of $797.8M as of 2026-06-30 is expected to fund operations to potential commercial launch of IMVT-1402 in GD [sec_mda · as of 2026-08-06]
- IMVT-1402 showed deep, dose-dependent IgG reductions with no or minimal off-target effects on albumin or LDL cholesterol in Phase 1 trials [sec_mda · as of 2026-08-06]
- Encouraging Week 16 data in difficult-to-treat rheumatoid arthritis, with strong response rates even in patients who had failed prior therapies [news · published 2026-05-22]
What to weigh
- Wider net losses reported: quarterly loss of US$147.86M and basic loss per share of US$0.73 for Q4 2026 [news · published 2026-05-22]
- Indefinite delay of batoclimab development indicates a strategic pivot that may reflect prior pipeline challenges [sec_mda · as of 2026-08-06]
- Future capital requirements will increase to fund clinical programs, manufacturing, and milestone payments, potentially straining cash runway [sec_mda · as of 2026-08-06]
From the filings
Quoted directly from source documents.
Cash position sufficient to fund operations to potential commercial launch
“We currently expect that our existing cash and cash equivalents as of June 30, 2026 of $797.8 million will be sufficient to fund our operating expenses and capital expenditure requirements, based on our current operating plan, to the potential commercial launch of IMVT-1402 in GD.”
SEC MD&A · August 6, 2026
IMVT-1402 shows deep IgG reductions with minimal off-target effects
“In the Phase 1 clinical trial, across all evaluated doses, IMVT-1402 demonstrated no or minimal reductions in albumin and no or minimal increases in LDL cholesterol levels, which are off-target effects observed in some anti-FcRn antibodies, including batoclimab.”
SEC MD&A · August 6, 2026
Company indefinitely delayed batoclimab to focus on IMVT-1402
“indefinitely delay further development of batoclimab and focus our resources fully on IMVT-1402.”
SEC MD&A · August 6, 2026
Risks & what to watch (3)›
Key risks
- Net loss trajectory — Wider net losses reported, with quarterly loss of US$147.86M and basic loss per share of US$0.73 for Q4 2026 [news · published 2026-05-22]
- Pipeline concentration risk — Indefinite delay of batoclimab leaves IMVT-1402 as sole clinical asset, increasing dependency on its success [sec_mda · as of 2026-08-06]
- Increasing capital requirements — Future capital needs will rise for clinical programs, manufacturing, and milestone payments, potentially pressuring cash runway [sec_mda · as of 2026-08-06]
What to watch
- Top-line results from IMVT-1402 proof-of-concept trial in CLE expected in second half of calendar year 2026 [sec_mda · as of 2026-05-20]
- Updates on IMVT-1402 program in difficult-to-treat rheumatoid arthritis expected in second half of calendar year 2026 [sec_mda · as of 2026-05-20]
- Top-line results from potentially registrational trial in SjD expected in calendar year 2028 [sec_mda · as of 2026-05-20]
- Top-line results from potentially registrational trial in CIDP expected in calendar year 2028 [sec_mda · as of 2026-08-06]
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Immunovant, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immunovant, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
19.2 months
D/E 0.16 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 32 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
216
Total value held
$2.66B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 16,947,888 | $421.0M |
| deep track capital, lp | 11,526,971 | $286.3M |
| blackrock, inc. | 6,574,497 | $163.3M |
| baker bros. advisors lp | 5,457,881 | $135.6M |
| state street corp | 4,537,929 | $112.7M |
| tcg crossover management, llc | 4,457,988 | $110.7M |
| morgan stanley | 3,876,877 | $96.3M |
| vanguard portfolio management llc | 3,704,905 | $92.0M |
| vanguard capital management llc | 3,620,050 | $89.9M |
| armistice capital, llc | 3,564,916 | $88.6M |
Showing top 10 of 216 institutional holders of Immunovant, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 21.9%
- Days to cover
- 13.2
- Shares short
- 19,500,601
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMVT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Immunovant, Inc.?
Immunovant is a clinical-stage immunology company developing IMVT-1402, an anti-FcRn monoclonal antibody, for autoimmune diseases, with a focus on generalized myasthenia gravis and other IgG-driven conditions.
Who is the CEO of Immunovant, Inc.?
Dr. Eric Venker M.D., Pharm.D. is the chief executive officer of Immunovant, Inc. (IMVT).
Where is Immunovant, Inc. headquartered?
Immunovant, Inc. (IMVT) is headquartered in Durham, NC, United States.
What therapeutic areas does Immunovant, Inc. focus on?
Immunovant, Inc. develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Dermatology, Musculoskeletal, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.